Who We Are > Organizations

Corporate and Institutional Partners

The business and institutional communities are integral partners in stemming the spread of viral diseases worldwide. Viral outbreaks, such as SARS-CoV-2 / COVID19, know no boundaries and spread rapidly beyond national borders. They are accompanied by uncertainty, social instability, and can cause significant losses to workforces, productivity, and revenue streams. Multinational corporations, businesses, and institutions with international interests are vital partners in preparations against current and future potential pandemics and in stopping the spread of viruses.

The main goal of corporate and institutional partnerships is to link the these organizations with leading medical virologists. In doing so, these partnerships support cutting edge viral research, drug and vaccine development, training activities, as well as aid in increased awareness of medical virology issues and strengthening international viral preparedness and response.

Corporate Partners

Expand to read more

For nearly three decades Abbott has monitored HIV and hepatitis viruses and identified mutations which help ensure the company’s diagnostic tests remain up to date through its Global Surveillance Program.

The surveillance program continues to be a pathway fueled by collaboration, enabling researchers to proactively evaluate and solve infectious disease challenges. In partnership with institutions around the world, the program has collected more than 78,000 samples containing HIV and hepatitis viruses, identified and characterized thousands of strains, and published 143 research papers to date to help the scientific community learn more about viruses and mutations. Most recently the company unveiled the Abbott Pandemic Defense Coalition – a first-of-its-kind global scientific and public health partnership dedicated to the early detection of — and rapid response to — future pandemic threats.

Learn more about Abbott’s surveillance work including its Pandemic Defense Coalition and recent HIV discovery.

Follow Abbott on Twitter: @AbbottNews

Expand to read more

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Expand to read more

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Institutional Partners

The Global Health Security Agenda (GHSA) was launched in February 2014 and is a growing partnership of over 50 nations, international organizations, and non-governmental stakeholders to help build countries’ capacity to help create a world safe and secure from infectious disease threats and elevate global health security as a national and global priority.

The Coalition for Epidemic Preparedness Innovations (CEPI) is a new alliance between governments, industry, academia, philanthropy, intergovernmental institutions, such as the WHO, and civil society. We exist to finance and coordinate the development of new vaccines to prevent and contain infectious disease epidemics.